Influence of olsalazine on gastrointestinal transit in ulcerative colitis

S S C Rao, N W Read, and C D Holdsworth

From the Gastrointestinal Unit, Royal Hallamshire Hospital, Sheffield

SUMMARY The effect of olsalazine on stool output and the transit of a solid radiolabelled meal through the stomach, small intestine and colon was studied in six patients with ulcerative colitis intolerant of sulphasalazine. Olsalazine 250 mg four times daily significantly accelerated gastric emptying (mean±SD: 45.3±24.2 min v 67.3±33.1 min, p<0.05), mouth to caecum transit time (242±41 min v 325±33 min, p<0.02) and whole gut transit time (60.5±26 h v 37.8±17.8 h, p<0.05). No significant changes were seen in mean daily stool weight (215±41 g v 162±62 g) and mean daily stool frequency (2.2±0.6 v 2.4±1.8). None of these patients developed diarrhoea, but acceleration of gastric and intestinal transit may be responsible for the diarrhoea reported in some patients taking this drug.

Sulphasalazine (SASP) consists of 5-aminosalicylic acid (5-ASA) and sulphapyridine linked together by an azo bond. 5-ASA has now been confirmed as the beneficial moiety of SASP for the treatment of ulcerative colitis.1 Olsalazine is a formulation of 5-ASA and has a similar structure to SASP except that another 5-ASA molecule is substituted for sulphapyridine.3 This formulation has now been shown to be effective in the treatment of colitis4 and is tolerated by 85% of patients intolerant of SASP.5,6 Up to 10% of patients are reported to have experienced an exacerbation of diarrhoea while taking olsalazine,7 however, an adverse effect only rarely seen with SASP.8 In order to study the pathophysiology of the diarrhoea induced by olsalazine, the effect of the drug on stool output and transit of a solid meal through the stomach, small intestine and colon was measured in patients with ulcerative colitis all of whom were intolerant of SASP. The clinical details of the patients and the adverse effects previously experienced with SASP are shown in Table 1. None of the patients had previously experienced an exacerbation of diarrhoea with SASP. The studies were not placebo controlled as the safety and tolerance of olsalazine was also being investigated and were not randomised as the drug has a long serum half life9 and it was thought to be unethical not to prescribe any medication while waiting for the drug to clear from the body. One of the six patients was taking 1-5 g/day of SASP and one other patient was taking 1-2 g/day of mesalazine, both of which were discontinued one week before the study. The remaining four patients were on no longterm therapy. The first study served as the

Table 1 Clinical details of patients with ulcerative colitis

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Disease extent</th>
<th>Disease activity</th>
<th>Adverse reaction to sulphasalazine</th>
<th>Duration of disease (yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 75</td>
<td>M</td>
<td>Total</td>
<td>Quiescent Rash</td>
<td>No</td>
<td>6</td>
</tr>
<tr>
<td>2 44</td>
<td>F</td>
<td>Distal</td>
<td>Quiescent Dyspepsia</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>3 66</td>
<td>F</td>
<td>Distal</td>
<td>Active Dyspepsia, headache, depression</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td>4 42</td>
<td>M</td>
<td>Proctitis</td>
<td>Quiescent Dyspepsia</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>5 70</td>
<td>F</td>
<td>Distal</td>
<td>Quiescent Rash</td>
<td>No</td>
<td>3</td>
</tr>
<tr>
<td>6 53</td>
<td>M</td>
<td>Distal</td>
<td>Quiescent Dyspepsia</td>
<td></td>
<td>3</td>
</tr>
</tbody>
</table>
control and no medication was taken except in the case of patient 3 (Table 1) who was on oral prednisolone sulphate which was continued. After completion of the first study, the patients were prescribed olsalazine (250 mg capsules), the dose of which was gradually increased over the first week to one capsule four times daily. After four weeks the meal transit study was repeated, giving one capsule with the meal.

Sigmoidoscopy and rectal biopsy were done a few days before each study to assess the activity of the disease. A full blood count, ESR, and liver biochemistry were also checked before each study.

The methods used for measuring transit were identical to those described previously. In brief, the meal consisted of 150 g mashed potato, 120 g baked beans, and 50 ml water. Tc-99m Te-Tc tin colloid 0.93 MBq and 50 segments (2 mm x 3 mm) of radioopaque tubing were incorporated in the mashed potato. All subjects ingested the meal after an overnight fast and gastric emptying was determined from radioactive counts recorded every 10 minutes by means of a single crystal scintillation detector (Type DMI-2, Nuclear Enterprises Ltd) positioned in front of the stomach over the area of maximum radioactivity. The time taken for the radioactive counts to fall to half the initial value (t1/2) was taken as an index of gastric emptying. Mouth to caecum transit was determined by measuring the time interval between eating the meal and a sustained rise in breath hydrogen concentration defined as a rise of 3 ppm over three consecutive 10 minute recordings. To record whole gut transit time, subjects were requested to collect the results of each bowel movement in separate polyethylene bags for a period of at least 72 hours and label them with the date and time. These were weighed and radiographed to determine the number of markers present. The time taken for the subject to void 50% of markers provided an index of the whole gut transit.

**Ethical Consideration**

The protocol for the study was approved on 6 November, 1984, by the Ethical Committee for the Sheffield Health Authority. All patients gave written informed consent for the studies to be carried out.

**Statistical Analysis**

The significance of the differences in measurements of gastrointestinal transit and stool output, between the first and second studies was determined using Student's paired t test.

**Results**

**Gastric Emptying (t1/2)**

The half time for gastric emptying was significantly accelerated during olsalazine administration (Fig. 1, Table 2).

**Table 1**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Baseline</th>
<th>Olsalazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>...</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 1** Effect of olsalazine on the gastrointestinal transit of a solid meal.
The results of this Table 2

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Olsalazine</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric emptying t1/2 (min)</td>
<td>67.3±3.3</td>
<td>45.3±2.4</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Mouth to caecum transit (min)</td>
<td>325±33</td>
<td>242±41</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Whole gut transit (h)</td>
<td>60.5±5.26</td>
<td>37.8±17.8</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Mean daily stool frequency</td>
<td>2.4±1.8</td>
<td>2.2±0.6</td>
<td>NS</td>
</tr>
<tr>
<td>Mean daily stool weight (g)</td>
<td>162±62</td>
<td>215±76</td>
<td>NS</td>
</tr>
</tbody>
</table>

Results are expressed as mean±SD.

MOUTH TO CAECUM TRANSIT
The mouth to caecum transit time was also significantly faster during ingestion of olsalazine (Fig. 1, Table 2).

WHOLE GUT TRANSIT TIME
The time taken to void 50% of markers was significantly accelerated during administration of olsalazine (Fig. 1, Table 2).

STOOL OUTPUT
The daily stool weight was higher during olsalazine treatment in five of the six patients but the increase was not statistically significant (Fig. 2, Table 2). There were no differences in the daily stool frequency between the two periods (Fig. 2, Table 2).

TOLERANCE OF OLSALAZINE
All six patients tolerated olsalazine without any adverse experience. No haematological or biochemical abnormalities were detected during the study. Five patients continued to be in remission at four weeks and the disease activity of patient 3 (Table 1) was unchanged.

Discussion
The results of this study show that olsalazine accelerated gastric emptying, mouth to caecum transit and whole gut transit time of a solid meal. The accelerated gastric emptying is presumably the result of a direct effect of the drug on gastric motility. The rapid small bowel transit could be either because of a direct action of the drug on small intestinal contractile activity or drug induced hypersecretion or diminished absorption, which could enhance propulsion by distending the lumen and inducing peristalsis. The net effect in either case will be an increased volume of fluid entering the colon from the small intestine. This is consistent with the observation that olsalazine increases ileostomy effluent. The normal colon will accommodate an additional load of 2–3 litres of fluid/day without diarrhoea but this capacity may be reduced in patients with ulcerative colitis. In our study, although the stool weight did increase in five of the six patients none of them reported an exacerbation of diarrhoea. This could be because the fact that five patients had distal colitis and only one had total colitis. In a large study, exacerbation of diarrhoea during olsalazine treatment was predominantly seen in patients with total colitis and was unusual in those with distal colitis. Moreover, ingestion of 100 ml dilute duphalac (Duphar) containing 20 g lactulose causes diarrhoea in patients with total colitis, but not in patients with distal colitis. These data suggest that while patients with distal colitis can absorb the increased fluid load from the ileum, induced by olsalazine, patients with total colitis fail to do so and may therefore experience diarrhoea.

A further reason for the low incidence of clinically evident diarrhoea produced by olsalazine is that intestinal transit is usually slow in patients with ulcerative colitis and olsalazine may reduce transit times to values that are very similar to those seen in normal subjects (mean±SD. mouth to caecum transit [min] 230±65, whole gut transit [h] 48±8±22.3). Indeed in those patients who develop hard stools that are difficult to evacuate, olsalazine could soften the stool.

The authors are grateful to Mrs C Brown and Mrs C Bruce for their technical assistance, to Pharmacia Limited for supply of Olsalazine capsules and to Mrs J Wilson for her secretarial help. Dr Rao is supported by a grant from the Special Trustees for the Former United Sheffield Hospitals.

References
Influence of olsalazine on gastrointestinal transit in ulcerative colitis

Influence of olsalazine on gastrointestinal transit in ulcerative colitis.
S S Rao, N W Read and C D Holdsworth

*Gut* 1987 28: 1474-1477
doi: 10.1136/gut.28.11.1474

Updated information and services can be found at:
[http://gut.bmj.com/content/28/11/1474](http://gut.bmj.com/content/28/11/1474)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections:

- Ulcerative colitis (1113)
- Stomach and duodenum (1689)
- Diarrhoea (663)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)